Hepatitis B and C track with higher macular degeneration risk in a nationwide Korean cohort
A nationwide Korean analysis has tied hepatitis B virus and hepatitis C virus infection to a higher risk of later age-related macular degeneration, adding a large population-based signal to a question that has remained thinly studied. The cohort was enormous: 12,386,563 adults aged 40 years and older who underwent health examinations in 2009–2010 and were followed through 2023 using National Health Insurance Service data. During follow-up, 388,652 participants developed incident AMD.
The scale matters because AMD is common, chronic, and clinically heterogeneous. Exudative disease tends to threaten central vision quickly through neovascular leakage and scarring, while nonexudative disease evolves through retinal pigment epithelium and photoreceptor degeneration. Viral hepatitis does not fit neatly into ophthalmology, yet chronic infection can drive systemic immune activation, vascular dysfunction, and inflammatory signaling that plausibly reach the retina and choroid. In that setting, a modest hazard ratio may still represent a meaningful public health burden when applied across millions of adults.
Stronger signal for nonexudative disease than for exudative AMD
Multivariable Cox proportional hazards models showed that HBV infection was associated with increased risk of exudative AMD (hazard ratio 1.18, 95% confidence interval 1.05–1.32) and an even larger increase in nonexudative AMD (hazard ratio 1.68, 95% confidence interval 1.60–1.76). HCV infection also tracked with elevated risk for both phenotypes, with a hazard ratio of 1.53 for exudative AMD (95% confidence interval 1.27–1.86) and 1.41 for nonexudative AMD (95% confidence interval 1.27–1.57).
The pattern is clinically interesting because the nonexudative association was stronger than the exudative association for HBV, while HCV showed elevated risk across both pathways. A biologic explanation is plausible even if this study cannot prove mechanism: chronic hepatitis can sustain inflammatory mediators, endothelial injury, and complement-related activity, all of which may intersect with retinal aging and drusen biology. The retinal pigment epithelium is highly sensitive to oxidative and inflammatory stress, so a systemic infectious burden may accelerate the same degenerative processes that ordinarily accumulate with age.
One sentence captures the practical implication: chronic viral hepatitis was linked to more, not less, later macular disease.
Women carried the stronger associations in sex-stratified analyses
Sex-stratified analyses suggested the associations were stronger in women. The abstract does not provide the sex-specific hazard ratios, so no finer numerical comparison can be drawn from the available text, but the direction is still notable. In a disease as prevalent as AMD, a sex difference in relative risk can matter as much as the absolute association itself, especially when screening and counseling decisions depend on layered risk rather than a single trigger.
Several pathways could explain why the relationship appeared more pronounced in women. Hormonal influences on immune regulation, differences in longevity, and variation in health-care use may all shape observed AMD incidence in large administrative cohorts. Age-related retinal degeneration is rarely the product of a single exposure, and hepatitis may act as one more pressure on an already vulnerable microvascular and immune environment.
Administrative data widen the reach but narrow the clinical detail
This study drew on insurance claims and diagnostic coding, which allows extraordinary sample size and long follow-up but also limits the biologic resolution available to clinicians. HBV and HCV infections were identified using diagnostic codes, and incident AMD was classified as exudative using Rare Intractable Disease registration codes and as nonexudative using Korean Classification of Diseases codes. That approach is efficient for population epidemiology, yet it does not capture viral load, treatment history, disease activity, smoking status, nutritional factors, family history of AMD, or retinal imaging features that would sharpen causal interpretation.
Those missing details matter at the bedside. A patient with chronic hepatitis and preserved vision is not automatically headed for AMD, and the study does not justify causal claims for an individual. Even so, the size of the association, the consistency across both AMD phenotypes, and the long observation window argue that chronic viral hepatitis may belong on the expanding list of systemic conditions relevant to retinal risk assessment.
The clinical message is not that hepatitis screening should be added to ophthalmology workflows for AMD prevention. It is narrower than that, and more immediate: patients with HBV or HCV may represent a group in which retinal vigilance deserves more attention, especially as age advances and degenerative eye disease becomes more likely.
The findings also fit a broader pattern seen in systemic inflammatory disease, where extrahepatic consequences emerge years before they are linked back to the primary infection. Retinal tissue depends on tightly regulated vascular supply and immune quiescence, so chronic hepatic infection may act indirectly through pathways that are easy to miss in routine clinic visits. The study design cannot establish whether antiviral treatment lowers AMD risk, whether infection duration matters, or whether the association differs by severity of liver disease.
What the cohort can and cannot settle
The nationwide design gives this analysis unusual statistical weight, but it still leaves unanswered questions about mechanism and prevention. No imaging-based AMD phenotyping is available from the abstract, and no treatment-response data are provided for antiviral therapy. The cohort also begins with adults who were already 40 years or older in 2009–2010, which means the results speak to midlife and older adults rather than to younger hepatitis carriers.
Even with those limits, the direction is hard to ignore. Both HBV and HCV were associated with later AMD, and the association extended to both exudative and nonexudative disease in a very large Korean population. The next step is not a sweeping change in eye screening policy; it is a more precise look at whether viral suppression, inflammatory burden, and duration of infection alter retinal risk over time.